NASDAQ:SVRA

Savara Q3 2026 Earnings Results & Report

Savara logo
$4.48 +0.01 (+0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.66 +0.19 (+4.13%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Savara beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.17 versus the -$0.1756 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Savara EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.1756
Beat/Miss
Beat by +$0.0056
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Savara Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.23 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Savara Q3 2026 Earnings FAQ

Savara (NASDAQ:SVRA) reported earnings of -$0.17 per share for Q3 2026, beating the consensus estimate of -$0.1756. The report was announced on Monday, November 9, 2026.

Savara Earnings Headlines

Savara: The Market May Be Overestimating Its FDA Risk
HC Wainwright Begins Coverage on Savara (NASDAQ:SVRA)
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Savara Announces New Employment Inducement Grant
Savara (SVRA) Set to Announce Earnings on Wednesday
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA) is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options.

Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Molgramostim is investigational; its availability and development status may change as clinical and regulatory work progresses. Savara’s business is centered on advancing this program and evaluating its potential to address unmet needs in rare respiratory disease.

View Savara Profile